Momenta, Teva, Novartis autoimmune news

Momenta and Novartis' Sandoz International GmbH generics unit filed suit in the U.S. District Court for the District of Massachusetts claiming that Teva's generic enoxaparin infringes Momenta's U.S. Patents Nos. 7,575,886 and 7,790,466, covering the production of enoxaparin. Teva, which has an ANDA for generic enoxaparin under review at FDA, said the suit is "without merit" and claims its product does not infringe the patents. In July, FDA approved the ANDA from Momenta and Sandoz for a generic version of enoxaparin. sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) markets Lovenox enoxaparin, a low-molecular weight heparin. Novartis reported $292 million in 3Q10 sales for the product. ...